C4 Therapeutics announces positive Phase 1 data for CFT7455 in relapsed/refractory multiple myeloma

C4 Therapeutics, Inc.

Monotherapy dose escalation complete; 22 patients, median 7 prior therapies; 1 PR at 75 µg daily in BCMA-refractory patient.
Combination with dexamethasone: 9 patients; 1 sCR and 1 PR at 37.5 µg daily, both BCMA refractory.
CFT7455 well tolerated; no DLTs leading to discontinuation; common Grade 3+ AE: neutropenia (n=11).
Optimal dosing schedule 14 days on/14 days off; immunomodulatory CD8+ T-cell activation observed.
Dose escalation continues for combination and NHL; full Phase 1 data expected in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.